Abstract
p38α MAPK, a key therapeutic target in HNSCC can be considered as a prognostic marker and is implicated in response to radiation-therapy (RT). We compared the outcome of treatment viz. RT (group-I) and concurrent-RT (combination of RT with chemotherapy or surgery, group-II) with respect to p38α MAPK in HNSCC. The case-controlled study was performed on 143 HNSCC patients. From these p38α estimation was done thrice only for 104 patients (52 each in group-I and II), at pre, during and post-therapy periods using surface Plasmon resonance (SPR) technology, ELISA and western blot analysis. In HNSCC the over-expressed p38α levels declined after treatments in both the groups. The patients receiving only RT had a lower p38α level than those treated with concurrent-RT (p=0.009). Hence, p38α was found to be responsive to RT in HNSCC and it may be useful in predicting the treatment outcome and further improve the prognosis of disease in addition to clinical parameters.
Keywords: p38α, HNSCC, radiation therapy, chemotherapy, surgery.
Current Cancer Therapy Reviews
Title:Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α
Volume: 10 Issue: 3
Author(s): Kamaldeep Gill, Rahul Kumar, Abhishek Gupta, Bidhu Kalyan Mohanti and Sharmistha Dey
Affiliation:
Keywords: p38α, HNSCC, radiation therapy, chemotherapy, surgery.
Abstract: p38α MAPK, a key therapeutic target in HNSCC can be considered as a prognostic marker and is implicated in response to radiation-therapy (RT). We compared the outcome of treatment viz. RT (group-I) and concurrent-RT (combination of RT with chemotherapy or surgery, group-II) with respect to p38α MAPK in HNSCC. The case-controlled study was performed on 143 HNSCC patients. From these p38α estimation was done thrice only for 104 patients (52 each in group-I and II), at pre, during and post-therapy periods using surface Plasmon resonance (SPR) technology, ELISA and western blot analysis. In HNSCC the over-expressed p38α levels declined after treatments in both the groups. The patients receiving only RT had a lower p38α level than those treated with concurrent-RT (p=0.009). Hence, p38α was found to be responsive to RT in HNSCC and it may be useful in predicting the treatment outcome and further improve the prognosis of disease in addition to clinical parameters.
Export Options
About this article
Cite this article as:
Gill Kamaldeep, Kumar Rahul, Gupta Abhishek, Mohanti Kalyan Bidhu and Dey Sharmistha, Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/1573394710666141128001358
DOI https://dx.doi.org/10.2174/1573394710666141128001358 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Molecular Design and Clinical Development of VEGFR Kinase Inhibitors
Current Topics in Medicinal Chemistry Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Tumor Promoters - Microcystin-LR, Nodularin and TNF-α and Human Cancer Development
Anti-Cancer Agents in Medicinal Chemistry Intracellular Proton Pumps as Targets in Chemotherapy: V-ATPases and Cancer
Current Pharmaceutical Design Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets Design, Development and Characterization of Topical Microemulsions of 5-Fluorouracil for the Treatment of Non Melanoma Skin Cancer and its Precursor Lesions.
Anti-Cancer Agents in Medicinal Chemistry Can Diabetes Heal?- From Observations to Perspectives
Current Diabetes Reviews Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Editorial [ Hot Topic: Targeting Tumor Angiogenesis: An Update (Guest Editor: Girolamo Ranieri)]
Current Medicinal Chemistry